Kezar Life Sciences, Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Clinical Advisory Committee
  • Pipeline
    • Overview
    • KZR-616
    • KZR-261
  • Our Science
    • Overview
    • Medical & Scientific Presentations
    • Publications
  • Clinical Trials
  • Investors & News
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Medical & Scientific Presentations

Our Science

Our Science

  • Overview
  • Medical & Scientific Presentations
  • Publications
Oct 23, 2020

KZR-616, A Selective Inhibitor of the Immunoproteasome: Preclinical and Clinical Mechanism of Action Studies in Lupus Nephritis

Kezar Life Sciences, Inc

American Society of Nephrology (ASN Kidney Week) 2020

Oct 22, 2020

ASN 2020: Treatment of SLE With or Without Nephritis With the Immunoproteasome Inhibitor KZR-616: Initial Results of the MISSION Study

Kezar Life Sciences, Inc

American Society of Nephrology (ASN Kidney Week) 2020

Sep 17, 2020

Treatment of Systemic Lupus Erythematosus With the Immunoproteasome Inhibitor KZR-616: Results From the First 5 Cohorts of the MISSION Study, an Open-label Phase 1b Dose-Escalation Study

Kezar Life Sciences, Inc

PANLAR 2020

May 29, 2020

Preclinical evaluation of KZR-261, a novel small molecule inhibitor of Sec61

Kezar Life Sciences, Inc.

American Society of Clinical Oncology (ASCO 2020)

Dec 7, 2019

Blocking Protein Secretion With Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Kezar Life Sciences, Inc

American Society of Hematology (ASH 2019)

Dec 6, 2019

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-cancer Small Molecule Inhibitor of Sec61

Kezar Life Sciences, Inc

American Society of Hematology (ASH 2019)

Nov 11, 2019

Treatment of Sle Patients With the Immunoproteasome Inhibitor Krz-616: Results From the First 3 Cohorts of an Open-label Phase 1b Dose Escalation Trial

Kezar Life Sciences, Inc

American College of Rheumatology (ACR 2019)

Nov 11, 2019

Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated With the Selective Immunoproteasome Inhibitor, Kzr-616

Kezar Life Sciences, Inc

American College of Rheumatology (ACR 2019)

Nov 11, 2019

Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of Kzr-616, a Selective Inhibitor of the Immunoproteasome

Kezar Life Sciences, Inc

American College of Rheumatology (ACR 2019)

Nov 9, 2019

Selective Inhibition of the Immunoproteasome With Kzr-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the Nzb/w Lupus Nephritis Model

Kezar Life Sciences, Inc

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • Next »
Kezar Life Sciences, Inc.
  • About Us
  • Pipeline
  • Our Science
  • Clinical Trials
  • Investors & News
  • Careers
Contact Us

4000 Shoreline Court , Suite 300
South San Francisco, CA 94080

Linkedin Facebook Twitter YouTube

© 2022 Kezar Life Sciences, Inc. All Rights Reserved.

Privacy Policy Disclaimer Sitemap